Vermillion, a molecular diagnostics company, has reported positive results from the intended use study for its peripheral artery disease (PAD) blood test, Vasclir.

The prospective double-blinded multicentre study enrolled about 1,000 subjects who met specific inclusion criteria for being at increased risk of having PAD, including smokers and diabetics aged 50 or above and the elderly aged 70 or above.

The aim of the study is to develop and validate a biomarker panel applicable to the intended use population.

The individual biomarkers beta 2 microglobulin (b2m), cystatin C and hsCRP has significantly different levels between PAD subjects and non-PAD subjects.

In the previous study, these biomarkers showed correlation to the ankle-brachial index (ABI).


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.